Cargando…

Assessment of Local Adverse Reactions to Subcutaneous Immunoglobulin (SCIG) in Clinical Trials

Detalles Bibliográficos
Autores principales:	Ballow, Mark, Wasserman, Richard L., Jolles, Stephen, Chapel, Helen, Berger, Mel, Misbah, Siraj A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2017
Materias:	Letter to Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5940704/ https://www.ncbi.nlm.nih.gov/pubmed/28695366 http://dx.doi.org/10.1007/s10875-017-0410-x

Ejemplares similares

Correction to: Assessment of Local Adverse Reactions to Subcutaneous Immunoglobulin (SCIG) in Clinical Trials
por: Ballow, Mark, et al.
Publicado: (2018)

Response to the Letter to the Editor Regarding “Assessment of Local Adverse Reactions to Subcutaneous Immunoglobulin (SCIG) in Clinical Trials”
por: Suez, Daniel, et al.
Publicado: (2017)

Ten-year population trends of immunoglobulin use, burden of adult antibody deficiency and feasibility of subcutaneous immunoglobulin (SCIg) replacement in Hong Kong Chinese
por: Kan, Andy Ka Chun, et al.
Publicado: (2022)

Implications to payers of switch from hospital-based intravenous immunoglobulin (IVIg) to home-based subcutaneous immunoglobulin (SCIg) therapy in patients with primary immunodeficiencies (PID) and secondary immunodeficiencies (SID) in Canada
por: Gerth, William C, et al.
Publicado: (2014)

New Frontiers in Subcutaneous Immunoglobulin Treatment
por: Jolles, Stephen, et al.
Publicado: (2011)

Hyaluronidase facilitated subcutaneous immunoglobulin in primary immunodeficiency
por: Jolles, Stephen
Publicado: (2013)

Evaluation of correlation between dose and clinical outcomes in subcutaneous immunoglobulin replacement therapy
por: Orange, J S, et al.
Publicado: (2012)

SCIg vs. IVIg: let’s give patients the choice!
por: Samaan, Kathryn K, et al.
Publicado: (2014)

Use of subcutaneous immunoglobulin in inflammatory myositis
por: Zhou, Alan L, et al.
Publicado: (2021)

Common infusion-related reactions to subcutaneous immunoglobulin therapy: Managing patient expectations
por: Wasserman, Richard L.
Publicado: (2008)

Long-term treatment of refractory myasthenia gravis with subcutaneous immunoglobulin
por: Kovács, Edina, et al.
Publicado: (2017)

Subcutaneous Immunoglobulins are a Valuable Treatment Option in Myasthenia Gravis
por: Garnero, Martina, et al.
Publicado: (2018)

Shift from intravenous or 16% subcutaneous replacement therapy to 20% subcutaneous immunoglobulin in patients with primary antibody deficiencies
por: Canessa, Clementina, et al.
Publicado: (2016)

Quality of Life Differences for Primary Immunodeficiency Patients on Home SCIG versus IVIG
por: Anterasian, Christine, et al.
Publicado: (2019)

Adverse cutaneous drug reactions
por: Adibi, Neda
Publicado: (2014)

Individualizing Therapy in CIDP: A Mini-Review Comparing the Pharmacokinetics of Ig With SCIg and IVIg
por: Beydoun, Said R., et al.
Publicado: (2021)

Raised immunoglobulin E levels are not predictive of allergic reactions to blood products
por: Khan, Sujoy, et al.
Publicado: (2014)

Therapeutic Use of Immunoglobulins
por: Stiehm, E. Richard, et al.
Publicado: (2010)

Hypopigmentation and subcutaneous fat, muscle atrophy after local corticosteroid injection
por: Park, Sun-Kyung, et al.
Publicado: (2013)

SCIG administration: A promising and patient convenient alternative for those receiving long-term IVIG
por: Hassini, Slim, et al.
Publicado: (2022)

Adverse drug reaction and causality assessment scales
por: Zaki, Syed Ahmed
Publicado: (2011)

Clinical causality assessment for adverse drug reactions
por: Parida, Satyen
Publicado: (2013)

Adverse drug reaction monitoring in psychiatry out-patient
por: Tandon, Vishal
Publicado: (2012)

Adverse drug reactions in the era of multi-morbidity and polypharmacy
por: Birriel, T. Javier, et al.
Publicado: (2015)

Subcutaneous Hematoma following Subcutaneous Emphysema: An Occult Association
por: Khandelwal, Ankur, et al.
Publicado: (2017)

Immunodeficient patient experience of emergency switch from intravenous to rapid push subcutaneous immunoglobulin replacement therapy during coronavirus disease 2019 shielding
por: Morgan, Clare, et al.
Publicado: (2022)

Bioavailability of IgG Administered by the Subcutaneous Route
por: Berger, Melvin, et al.
Publicado: (2013)

Treatment Satisfaction with Subcutaneous Immunoglobulin Replacement Therapy in Patients with Primary Immunodeficiency: a Pooled Analysis of Six Hizentra® Studies
por: Mallick, Rajiv, et al.
Publicado: (2018)

Rheumatic Immuno-related Adverse Events following Immunotherapy with Checkpoint Inhibitors: Adverse Drug Reaction, or Other?
por: Manzo, Ciro
Publicado: (2021)

Oxcarbazepine-induced tardive dyskinesia: A rare adverse reaction
por: Hergüner, M. Özlem, et al.
Publicado: (2010)

Caplacizumab: frequent local skin reactions
por: Kaufeld, Jessica, et al.
Publicado: (2020)

Pediatric subset of primary immunodeficiency patients treated with SCIG: post hoc analysis of SHIFT and IBIS pooled data
por: Moschese, Viviana, et al.
Publicado: (2020)

Subcutaneous sarcoidosis on the digits
por: Norikawa, Natsumi, et al.
Publicado: (2020)

Subcutaneous Infection with Dirofilaria spp. Nematode in Human, France
por: Eberhard, Mark L.
Publicado: (2013)

Adverse drug reactions due to ophthalmic drugs: Reporting system in India
por: Kalaiselvan, Vivekanandan, et al.
Publicado: (2016)

Incident Reporting of Adverse Drug Reaction to Intravenous Ranitidine in an Emergency Department
por: Sud, Saurabh, et al.
Publicado: (2018)

Serious adverse drug reactions with hydroxychloroquine: a pharmacovigilance study in Vigibase®
por: Montastruc, Jean-Louis, et al.
Publicado: (2020)

Adverse drug reactions with naltrexone: Experience from an addiction treatment center
por: Sarkar, Siddharth, et al.
Publicado: (2021)

COVID-19 Vaccine Uptake and Efficacy in a National Immunodeficiency Cohort
por: Ponsford, Mark J., et al.
Publicado: (2022)

Adverse Reactions to Intravenous Immunoglobulins - Our Experience
por: Kareva, Lidija, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_ujdgd3bi1crm9l8betje2dlffd